Biotech Showcase
Join us virtually
January 10–12, 2022 &January 17–19, 2022

Spiro Rombotis
President and CEO at Cyclacel Pharmaceuticals

Profile

Mr. Rombotis joined Cyclacel as its first CEO in 1997 and has served over 35 years at three public biotechs and two pharmas. He participated in in-licensing, clinical development, regulatory approval, partnering and commercial launch of several drugs, mainly in inflammation and hematology/oncology, including Abelcet®, Evacet/Myocet®, ProHance®, Remicade® and Reopro®. Major functional roles included international operations and business development as Vice President at Liposome (subsequently acquired by Elan) and previously Vice President in the pharmaceuticals division of Bristol-Myers Squibb. He began his career in the early ’80s, after training at Novartis, as one of the first employees of Centocor (subsequently acquired by Johnson & Johnson). He holds an MBA and MPH (Hospital & Health Services Management) with honors, Kellogg School of Management, Northwestern University and a BA, Williams College. He serves on the Board of Trustees of BioNJ, the NJ biotech association.

Agenda Sessions

  • Outsmarting Cancer: Next Generation Therapies

    08:00